What does BIOMEDICS do?

BIOMEDICS is a healthcare practice in Wervik. Public Limited, started on 30 October 1992, 1 establishment.

What is the address of BIOMEDICS?

The registered office of BIOMEDICS is located at Menenstraat 104, 8940 Wervik.

Is BIOMEDICS still active?

Yes. According to the CBE (30 October 2026) BIOMEDICS is active, legal situation “Normale toestand”, started on 30 October 1992.

Is BIOMEDICS registered on Peppol?

No, BIOMEDICS is currently not registered on the Peppol network.

What is the enterprise number of BIOMEDICS?

The enterprise number of BIOMEDICS is BE0448523941.

When was BIOMEDICS founded?

BIOMEDICS was founded on 30 October 1992.

Who are the directors of BIOMEDICS?

According to the 2025 annual accounts, the directors of BIOMEDICS are: DEBA PHARMA NV, FACTIS BV.

Is BIOMEDICS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 October 1992; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did BIOMEDICS make in 2025?

BIOMEDICS posted a profit after taxes of € 64,842 in financial year 2025.

What is the revenue of BIOMEDICS?

As a small company, BIOMEDICS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 196,157.

How much does an employee at BIOMEDICS earn?

The average wage cost per full-time employee at BIOMEDICS was € 57,300 in 2025: staff costs of € 103,206 for 1.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does BIOMEDICS have?

According to the 2025 annual accounts, BIOMEDICS has 1.8 full-time equivalents (FTE).

Does BIOMEDICS have a website?

Yes, BIOMEDICS has a website at labobiomedics.be.

BIOMEDICS (Public Limited) - Wervik - BE0448523941

Dossier BIOMEDICS, printed on 30 October 2026 from databakkes.be/en/0448523941/biomedics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

BIOMEDICS from Wervik, company number BE0448523941, closed financial year 2025 with a result of € 64,842 after tax. For that financial year BIOMEDICS recorded a gross margin of € 196,157 and equity of € 233,990. Compared with financial year 2024, the result moved from € 97,127 to € 64,842. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 25, 2026.

What it is worth Growing

€ 233,990

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 64,842

▼ 33% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 193,712

▼ 19% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 64,000 paid out

99 % of the profit went to the shareholders, mostly to INFICOM (50 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

1.8

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 103,206

▲ 6% vs 2024

€ 57,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 7,132

▲ € 6,586 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3,105

▼ 34% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 11,645

▲ 7% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 251,002 Gross margin 2022: € 251,002 First fiscal year in the series	€ 254,768 Gross margin 2023: € 254,768 ▲ 2% vs 2022 (€ 251,002) Favourable step	€ 231,564 Gross margin 2024: € 231,564 ▼ 9% vs 2023 (€ 254,768) Unfavourable step	€ 196,157 Gross margin 2025: € 196,157 ▼ 15% vs 2024 (€ 231,564) Unfavourable step	▼ 15%
Profit after taxes	€ 113,496 Profit after taxes 2022: € 113,496 First fiscal year in the series	€ 120,076 Profit after taxes 2023: € 120,076 ▲ 6% vs 2022 (€ 113,496) Favourable step	€ 97,127 Profit after taxes 2024: € 97,127 ▼ 19% vs 2023 (€ 120,076) Unfavourable step	€ 64,842 Profit after taxes 2025: € 64,842 ▼ 33% vs 2024 (€ 97,127) Unfavourable step	▼ 33%
Equity	€ 231,944 Equity 2022: € 231,944 First fiscal year in the series	€ 232,020 Equity 2023: € 232,020 Unchanged (€ 231,944) Favourable step	€ 233,148 Equity 2024: € 233,148 Unchanged (€ 232,020) Favourable step	€ 233,990 Equity 2025: € 233,990 Unchanged (€ 233,148) Favourable step
Total debts	€ 160,429 Total debts 2022: € 160,429 First fiscal year in the series	€ 135,820 Total debts 2023: € 135,820 ▼ 15% vs 2022 (€ 160,429) Favourable step	€ 111,574 Total debts 2024: € 111,574 ▼ 18% vs 2023 (€ 135,820) Favourable step	€ 78,750 Total debts 2025: € 78,750 ▼ 29% vs 2024 (€ 111,574) Favourable step	▼ 29%
Cash	€ 261,426 Cash 2022: € 261,426 First fiscal year in the series	€ 267,927 Cash 2023: € 267,927 ▲ 2% vs 2022 (€ 261,426) Favourable step	€ 239,570 Cash 2024: € 239,570 ▼ 11% vs 2023 (€ 267,927) Unfavourable step	€ 193,712 Cash 2025: € 193,712 ▼ 19% vs 2024 (€ 239,570) Unfavourable step	▼ 19%
Land & buildings	€ 79,836 Land & buildings 2022: € 79,836 First fiscal year in the series	€ 77,484 Land & buildings 2023: € 77,484 ▼ 3% vs 2022 (€ 79,836) Unchanged	€ 75,132 Land & buildings 2024: € 75,132 ▼ 3% vs 2023 (€ 77,484) Unchanged	€ 72,780 Land & buildings 2025: € 72,780 ▼ 3% vs 2024 (€ 75,132) Unchanged	▼ 3%
Retained profit	€ 169,944 Retained profit 2022: € 169,944 First fiscal year in the series	€ 170,020 Retained profit 2023: € 170,020 Unchanged (€ 169,944) Favourable step	€ 171,148 Retained profit 2024: € 171,148 ▲ 1% vs 2023 (€ 170,020) Favourable step	€ 171,990 Retained profit 2025: € 171,990 Unchanged (€ 171,148) Favourable step
Dividend	€ 112,000 Dividend 2022: € 112,000 First fiscal year in the series	€ 120,000 Dividend 2023: € 120,000 ▲ 7% vs 2022 (€ 112,000) Unchanged	€ 96,000 Dividend 2024: € 96,000 ▼ 20% vs 2023 (€ 120,000) Unchanged	€ 64,000 Dividend 2025: € 64,000 ▼ 33% vs 2024 (€ 96,000) Unchanged	▼ 33%
Balance sheet total	€ 392,373 Balance sheet total 2022: € 392,373 First fiscal year in the series	€ 367,840 Balance sheet total 2023: € 367,840 ▼ 6% vs 2022 (€ 392,373) Unchanged	€ 344,722 Balance sheet total 2024: € 344,722 ▼ 6% vs 2023 (€ 367,840) Unchanged	€ 312,739 Balance sheet total 2025: € 312,739 ▼ 9% vs 2024 (€ 344,722) Unchanged	▼ 9%
Employees (FTE)	1.8 Employees (FTE) 2022: 1.8 First fiscal year in the series	1.9 Employees (FTE) 2023: 1.9 ▲ 0.1 vs 2022 (1.8) Unchanged	1.9 Employees (FTE) 2024: 1.9 Unchanged (1.9) Unchanged	1.8 Employees (FTE) 2025: 1.8 ▼ 0.1 vs 2024 (1.9) Unchanged	▼ 0.1

Key figures of BIOMEDICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BIOMEDICS?

What happened at BIOMEDICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 DEBA PHARMA NV stepped down as director. NBB
2028 FACTIS BV stepped down as director. NBB
Jul 25, 2026 New annual accounts for financial year 2025: profit of € 64,842 (▼ 33% vs 2024). Source: NBB ↗
2022 DEBA PHARMA NV became a director. NBB
2022 FACTIS BV became a director. NBB
Oct 30, 1992 New establishment in Wervik. KBO
Oct 30, 1992 Start of the company according to the CBE. KBO

In short

From € 113,496 profit in 2022 to € 64,842 profit in 2025.

Paid € 134,357 in corporate taxes since 2022.

Best year ever: 2023, with € 120,076 profit.

On average € 109,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

INFICOM 50%

FACTIS 50%

The stake of INFICOM, FACTIS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

BIOMEDICS

The shares are held by INFICOM (50%) and FACTIS (50%).

Directors

According to the 2025 annual accounts

DEBA PHARMA NV

Managing director · represented by DEJONGHE JOHAN

since 2022 · until 2028

FACTIS BV

Managing director · represented by DEYLGAT ELS

since 2022 · until 2028

Shareholders

INFICOM

50%

FACTIS

50%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Menenstraat 104

8940 Wervik

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTP labobiomedics.be

Technologies

Apache

Hosting & Email

Email provider

Microsoft 365

Hosting

PROXIMUS-ISP-AS, BE

Website info

HTTPS Nee

Features

Security

✗ HTTPS

✓ SPF

✗ DMARC

Details

Company number

0448.523.941

VAT number

BE 0448.523.941

Registered office

Menenstraat 104, 8940 Wervik

Names & denominations

BIOMEDICS

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

30 October 1992

Peppol

Not registered

Contact

labobiomedics.be

Activities · NACE

Activiteiten van medische beeldvorming en medische laboratoria

Medische laboratoria

Activiteiten van medische laboratoria

View on CBE Public ↗ Annual accounts (NBB) ↗

BIOMEDICS

Warning lights

Financials

What happened to BIOMEDICS?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions